Molecular similarities between primary peritoneal and primary ovarian carcinomas

The objective of this paper was to characterize expression patterns of biologic markers to distinguish papillary serous peritoneal carcinoma (PPC) from papillary serous ovarian carcinoma (POC). Immunohistochemical analysis of HER-2/neu, p53, bcl-2, and nm23-H1 expression was performed on archival paraffin-embedded tissues. Antigen expression was compared at ovarian and extra-ovarian sites. Thirty-two PPC cases were compared to 18 POC cases. Mean age, stage, grade, and survival outcome were comparable between the two groups. Antigen expression patterns were not significantly different between PPC and POC for the four markers studied. In all cases, nm23-H1 was expressed. Conversely, bcl-2 was expressed at only a single tissue site in three of 32 (9.4%) PPC cases and in one of 18 (5.6%) POC cases. Eleven of 32 (34.4%) PPC cases overexpressed HER-2/neu, vs. four of 18 (22.2%) POC cases. P53 staining results were positive in 23 of 32 (71.9%) PPC and 13 of 18 (72.2%) POC cases. Intrapatient antigen expression was identical at primary and metastatic tumor sites in 50% of the POC and 48.4% of the PPC cases. We conclude that PPC and POC have a comparable immunohistochemical phenotype for these four molecular markers, which is reflected by their similar clinical courses.

[1]  I. Bukovsky,et al.  Immunohistochemical Comparison of Primary Peritoneal and Primary Ovarian Serous Papillary Carcinoma , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  I. Bukovsky,et al.  Primary peritoneal serous papillary carcinoma: A new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer , 2001, International Journal of Gynecologic Cancer.

[3]  R. L. Baldwin,et al.  Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. , 1999, American journal of obstetrics and gynecology.

[4]  L. Blumenson,et al.  Prognostic factors in extraovarian primary peritoneal carcinoma. , 1998, Gynecologic oncology.

[5]  S. Finkelstein,et al.  A case‐matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma , 1997, Cancer.

[6]  B. Karlan,et al.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.

[7]  F. Oesch,et al.  Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. , 1996, Gynecologic oncology.

[8]  J. Warwick,et al.  The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. , 1996, Cancer research.

[9]  G. Baretton,et al.  bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. , 1996, American journal of clinical pathology.

[10]  W. Cliby,et al.  Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma. , 1996, Gynecologic oncology.

[11]  E. Sivan,et al.  Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. , 1996, Gynecologic oncology.

[12]  M. Marone,et al.  nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Fukumoto,et al.  Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. , 1995, British Journal of Cancer.

[14]  K. Tham,et al.  Papillary serous carcinoma of the peritoneum. , 1995, Journal of obstetrics and gynaecology.

[15]  R. Berkowitz,et al.  Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. , 1995, Cancer research.

[16]  L. Bloss,et al.  Extraovarian peritoneal serous papillary carcinoma: A case‐control retrospective comparison to papillary adenocarcinoma of the ovary , 1994, Gynecologic oncology.

[17]  M. Killackey,et al.  Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. , 1993, Gynecologic oncology.

[18]  M. Birrer,et al.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.

[19]  D. Carter,et al.  NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. , 1992, Gynecologic oncology.

[20]  R. Zarbo,et al.  A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. , 1990, Human pathology.

[21]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[22]  I. Cohen,et al.  Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. , 1990, Gynecologic oncology.

[23]  D. Gershenson,et al.  Papillary serous carcinoma of the peritoneum , 1990, Obstetrics and gynecology.

[24]  M. Friedlander,et al.  Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases , 1989, Cancer.

[25]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[26]  S. Mills,et al.  Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. , 1988, The American journal of surgical pathology.

[27]  M. Piver,et al.  Peritoneal papillary carcinoma. , 1988, Gynecologic oncology.

[28]  A. Blaustein,et al.  Serous Surface Papillary Carcinoma of the Ovary: A Clinicopathologic Study of 16 Cases , 1982, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[29]  J. Churg,et al.  Papillary tumors of the peritoneum in women: mesothelioma or papillary carcinoma. , 1977, American journal of obstetrics and gynecology.

[30]  P. Steeg,et al.  Nm23 and breast cancer metastasis , 2004, Breast Cancer Research and Treatment.

[31]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[32]  M. Swerdlow.  Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. , 1959, American journal of obstetrics and gynecology.